Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16

1.

Diverse Brain Myeloid Expression Profiles Reveal Distinct Microglial Activation States and Aspects of Alzheimer's Disease Not Evident in Mouse Models.

Friedman BA, Srinivasan K, Ayalon G, Meilandt WJ, Lin H, Huntley MA, Cao Y, Lee SH, Haddick PCG, Ngu H, Modrusan Z, Larson JL, Kaminker JS, van der Brug MP, Hansen DV.

Cell Rep. 2018 Jan 16;22(3):832-847. doi: 10.1016/j.celrep.2017.12.066.

2.

Selective Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12) with Activity in a Model of Alzheimer's Disease.

Patel S, Meilandt WJ, Erickson RI, Chen J, Deshmukh G, Estrada AA, Fuji RN, Gibbons P, Gustafson A, Harris SF, Imperio J, Liu W, Liu X, Liu Y, Lyssikatos JP, Ma C, Yin J, Lewcock JW, Siu M.

J Med Chem. 2017 Oct 12;60(19):8083-8102. doi: 10.1021/acs.jmedchem.7b00843. Epub 2017 Sep 20.

PMID:
28929759
3.

Widespread brain distribution and activity following i.c.v. infusion of anti-β-secretase (BACE1) in nonhuman primates.

Yadav DB, Maloney JA, Wildsmith KR, Fuji RN, Meilandt WJ, Solanoy H, Lu Y, Peng K, Wilson B, Chan P, Gadkar K, Kosky A, Goo M, Daugherty A, Couch JA, Keene T, Hayes K, Nikolas LJ, Lane D, Switzer R, Adams E, Watts RJ, Scearce-Levie K, Prabhu S, Shafer L, Thakker DR, Hildebrand K, Atwal JK.

Br J Pharmacol. 2017 Nov;174(22):4173-4185. doi: 10.1111/bph.14021. Epub 2017 Oct 6.

PMID:
28859225
4.

Loss of dual leucine zipper kinase signaling is protective in animal models of neurodegenerative disease.

Le Pichon CE, Meilandt WJ, Dominguez S, Solanoy H, Lin H, Ngu H, Gogineni A, Sengupta Ghosh A, Jiang Z, Lee SH, Maloney J, Gandham VD, Pozniak CD, Wang B, Lee S, Siu M, Patel S, Modrusan Z, Liu X, Rudhard Y, Baca M, Gustafson A, Kaminker J, Carano RAD, Huang EJ, Foreman O, Weimer R, Scearce-Levie K, Lewcock JW.

Sci Transl Med. 2017 Aug 16;9(403). pii: eaag0394. doi: 10.1126/scitranslmed.aag0394.

5.

BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats.

Weber M, Wu T, Meilandt WJ, Dominguez SL, Solanoy HO, Maloney JA, Ngu H, Baca M, Kung C, Lima L, Earr TK, Fleck D, Shields SD, Forrest WF, Foreman O, Warming S, Watts RJ, Scearce-Levie K.

Sci Rep. 2017 Mar 10;7:44249. doi: 10.1038/srep44249.

6.

Characterization of a sensitive mouse Aβ40 PD biomarker assay for Alzheimer's disease drug development in wild-type mice.

Lu Y, Hoyte K, Montgomery WH, Luk W, He D, Meilandt WJ, Zuchero YJ, Atwal JK, Scearce-Levie K, Watts RJ, DeForge LE.

Bioanalysis. 2016 May;8(10):1067-75. doi: 10.4155/bio-2016-0003. Epub 2016 Apr 20.

PMID:
27094761
7.

Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.

Yu YJ, Atwal JK, Zhang Y, Tong RK, Wildsmith KR, Tan C, Bien-Ly N, Hersom M, Maloney JA, Meilandt WJ, Bumbaca D, Gadkar K, Hoyte K, Luk W, Lu Y, Ernst JA, Scearce-Levie K, Couch JA, Dennis MS, Watts RJ.

Sci Transl Med. 2014 Nov 5;6(261):261ra154. doi: 10.1126/scitranslmed.3009835.

8.

Chronic GluN2B antagonism disrupts behavior in wild-type mice without protecting against synapse loss or memory impairment in Alzheimer's disease mouse models.

Hanson JE, Meilandt WJ, Gogineni A, Reynen P, Herrington J, Weimer RM, Scearce-Levie K, Zhou Q.

J Neurosci. 2014 Jun 11;34(24):8277-88. doi: 10.1523/JNEUROSCI.5106-13.2014.

9.

A death receptor 6-amyloid precursor protein pathway regulates synapse density in the mature CNS but does not contribute to Alzheimer's disease-related pathophysiology in murine models.

Kallop DY, Meilandt WJ, Gogineni A, Easley-Neal C, Wu T, Jubb AM, Yaylaoglu M, Shamloo M, Tessier-Lavigne M, Scearce-Levie K, Weimer RM.

J Neurosci. 2014 May 7;34(19):6425-37. doi: 10.1523/JNEUROSCI.4963-13.2014.

10.

Addressing safety liabilities of TfR bispecific antibodies that cross the blood-brain barrier.

Couch JA, Yu YJ, Zhang Y, Tarrant JM, Fuji RN, Meilandt WJ, Solanoy H, Tong RK, Hoyte K, Luk W, Lu Y, Gadkar K, Prabhu S, Ordonia BA, Nguyen Q, Lin Y, Lin Z, Balazs M, Scearce-Levie K, Ernst JA, Dennis MS, Watts RJ.

Sci Transl Med. 2013 May 1;5(183):183ra57, 1-12. doi: 10.1126/scitranslmed.3005338.

11.

GluN2B antagonism affects interneurons and leads to immediate and persistent changes in synaptic plasticity, oscillations, and behavior.

Hanson JE, Weber M, Meilandt WJ, Wu T, Luu T, Deng L, Shamloo M, Sheng M, Scearce-Levie K, Zhou Q.

Neuropsychopharmacology. 2013 Jun;38(7):1221-33. doi: 10.1038/npp.2013.19. Epub 2013 Jan 22.

12.

A therapeutic antibody targeting BACE1 inhibits amyloid-β production in vivo.

Atwal JK, Chen Y, Chiu C, Mortensen DL, Meilandt WJ, Liu Y, Heise CE, Hoyte K, Luk W, Lu Y, Peng K, Wu P, Rouge L, Zhang Y, Lazarus RA, Scearce-Levie K, Wang W, Wu Y, Tessier-Lavigne M, Watts RJ.

Sci Transl Med. 2011 May 25;3(84):84ra43. doi: 10.1126/scitranslmed.3002254.

13.

Neprilysin overexpression inhibits plaque formation but fails to reduce pathogenic Abeta oligomers and associated cognitive deficits in human amyloid precursor protein transgenic mice.

Meilandt WJ, Cisse M, Ho K, Wu T, Esposito LA, Scearce-Levie K, Cheng IH, Yu GQ, Mucke L.

J Neurosci. 2009 Feb 18;29(7):1977-86. doi: 10.1523/JNEUROSCI.2984-08.2009.

14.

Enkephalin elevations contribute to neuronal and behavioral impairments in a transgenic mouse model of Alzheimer's disease.

Meilandt WJ, Yu GQ, Chin J, Roberson ED, Palop JJ, Wu T, Scearce-Levie K, Mucke L.

J Neurosci. 2008 May 7;28(19):5007-17. doi: 10.1523/JNEUROSCI.0590-08.2008.

15.

Role of hippocampal CA3 mu-opioid receptors in spatial learning and memory.

Meilandt WJ, Barea-Rodriguez E, Harvey SA, Martinez JL Jr.

J Neurosci. 2004 Mar 24;24(12):2953-62.

Supplemental Content

Loading ...
Support Center